US563536A
(en)
|
|
1896-07-07 |
|
Bracket for swinging stages |
US914623A
(en)
|
1908-08-19 |
1909-03-09 |
Henry H Williams |
Process in the manufacture of generating-plates for x-ray machines.
|
US1051266A
(en)
|
1910-09-26 |
1913-01-21 |
George I Rockwood |
Apparatus for operating alarms or other devices.
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4897445A
(en)
|
1986-06-27 |
1990-01-30 |
The Administrators Of The Tulane Educational Fund |
Method for synthesizing a peptide containing a non-peptide bond
|
EP0281604B1
(fr)
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Molecules de liaison de chaines de polypeptide simples
|
DE3642912A1
(de)
|
1986-12-16 |
1988-06-30 |
Leybold Ag |
Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
CA1341245C
(fr)
|
1988-01-12 |
2001-06-05 |
F. Hoffmann-La Roche Ag |
Virus recombinant de la vaccine derive du virus modifie ankara
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5744166A
(en)
|
1989-02-25 |
1998-04-28 |
Danbiosyst Uk Limited |
Drug delivery compositions
|
US5100587A
(en)
|
1989-11-13 |
1992-03-31 |
The United States Of America As Represented By The Department Of Energy |
Solid-state radioluminescent zeolite-containing composition and light sources
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US5179993A
(en)
|
1991-03-26 |
1993-01-19 |
Hughes Aircraft Company |
Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
|
CA2103059C
(fr)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Methode de production d'anticorps humanises
|
US6011146A
(en)
|
1991-11-15 |
2000-01-04 |
Institut Pasteur |
Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
|
US5734023A
(en)
|
1991-11-19 |
1998-03-31 |
Anergen Inc. |
MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
ES2341666T3
(es)
|
1991-12-02 |
2010-06-24 |
Medimmune Limited |
Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
US5747323A
(en)
|
1992-12-31 |
1998-05-05 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Retroviral vectors comprising a VL30-derived psi region
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
FR2707091B1
(fr)
|
1993-06-30 |
1997-04-04 |
Cohen Haguenauer Odile |
Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
|
US5820866A
(en)
|
1994-03-04 |
1998-10-13 |
National Jewish Center For Immunology And Respiratory Medicine |
Product and process for T cell regulation
|
DE699079T1
(de)
|
1994-03-07 |
1997-09-25 |
Dendritech Inc |
Bioaktive und/oder gezielte dendrimere-konjugate
|
FR2719316B1
(fr)
|
1994-04-28 |
1996-05-31 |
Idm |
Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
|
US5851806A
(en)
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
EP0784690B1
(fr)
|
1994-06-10 |
2006-08-16 |
Genvec, Inc. |
Systemes de vecteurs adenoviraux et lignees cellulaires complementaires
|
EP0769063A1
(fr)
|
1994-06-27 |
1997-04-23 |
The Johns Hopkins University |
Systeme de transport de gene cible
|
US5972707A
(en)
|
1994-06-27 |
1999-10-26 |
The Johns Hopkins University |
Gene delivery system
|
FR2722506B1
(fr)
|
1994-07-13 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucleiques, preparation et utilisations
|
US7074904B2
(en)
|
1994-07-29 |
2006-07-11 |
Altor Bioscience Corporation |
MHC complexes and uses thereof
|
US5559099A
(en)
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US5965541A
(en)
|
1995-11-28 |
1999-10-12 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
FR2727689A1
(fr)
|
1994-12-01 |
1996-06-07 |
Transgene Sa |
Nouveau procede de preparation d'un vecteur viral
|
EP0790837A1
(fr)
|
1994-12-21 |
1997-08-27 |
Novartis AG |
Conjugues oligonucleotide-dendrimere
|
US5635363A
(en)
|
1995-02-28 |
1997-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5837520A
(en)
|
1995-03-07 |
1998-11-17 |
Canji, Inc. |
Method of purification of viral vectors
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
IL122290A0
(en)
|
1995-06-07 |
1998-04-05 |
Inex Pharmaceuticals Corp |
Lipid-nucleic acid complex its preparation and use
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
SI0833934T2
(sl)
|
1995-06-15 |
2013-04-30 |
Crucell Holland B.V. |
Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
|
FR2737222B1
(fr)
|
1995-07-24 |
1997-10-17 |
Transgene Sa |
Nouveaux vecteurs viraux et lignee pour la therapie genique
|
US5837511A
(en)
|
1995-10-02 |
1998-11-17 |
Cornell Research Foundation, Inc. |
Non-group C adenoviral vectors
|
US5869270A
(en)
|
1996-01-31 |
1999-02-09 |
Sunol Molecular Corporation |
Single chain MHC complexes and uses thereof
|
WO1997035996A1
(fr)
|
1996-03-25 |
1997-10-02 |
Transgene S.A. |
Lignee cellulaire d'encapsidation a base de cellules 293 humaines
|
CA2177085C
(fr)
|
1996-04-26 |
2007-08-14 |
National Research Council Of Canada |
Lignees de cellules complements e1 de l'adenovirus
|
CZ438398A3
(cs)
|
1996-07-01 |
1999-03-17 |
Rhone-Poulenc Rorer S. A. |
Způsob přípravy rekombinantních adenovirů
|
US6211342B1
(en)
|
1996-07-18 |
2001-04-03 |
Children's Hospital Medical Center |
Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
|
US6348584B1
(en)
|
1996-10-17 |
2002-02-19 |
John Edward Hodgson |
Fibronectin binding protein compounds
|
DE69739961D1
(de)
|
1996-12-13 |
2010-09-23 |
Schering Corp |
Methoden zur Virus-Reinigung
|
FR2759382A1
(fr)
|
1997-02-10 |
1998-08-14 |
Transgene Sa |
Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
|
FR2760193B1
(fr)
|
1997-02-28 |
1999-05-28 |
Transgene Sa |
Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
|
EP0973866A4
(fr)
|
1997-03-04 |
2000-04-19 |
Baxter Int |
Lignees cellulaires de complementation de la region e1 d'un adenovirus
|
US6268411B1
(en)
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
US6020191A
(en)
|
1997-04-14 |
2000-02-01 |
Genzyme Corporation |
Adenoviral vectors capable of facilitating increased persistence of transgene expression
|
US6673901B2
(en)
|
1997-06-12 |
2004-01-06 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
WO1998056370A2
(fr)
|
1997-06-13 |
1998-12-17 |
Johns Hopkins University School Of Medicine |
Nanospheres therapeutiques
|
AU741130B2
(en)
|
1997-09-16 |
2001-11-22 |
Oregon Health Sciences University |
Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
|
US6232445B1
(en)
|
1997-10-29 |
2001-05-15 |
Sunol Molecular Corporation |
Soluble MHC complexes and methods of use thereof
|
US5981225A
(en)
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6113913A
(en)
|
1998-06-26 |
2000-09-05 |
Genvec, Inc. |
Recombinant adenovirus
|
US6440442B1
(en)
|
1998-06-29 |
2002-08-27 |
Hydromer, Inc. |
Hydrophilic polymer blends used for dry cow therapy
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
DE60029195T2
(de)
|
1999-02-22 |
2007-06-28 |
Transgene S.A. |
Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
|
DE60043126D1
(de)
|
1999-05-17 |
2009-11-19 |
Crucell Holland Bv |
Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten
|
US6913922B1
(en)
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
EP1964573B1
(fr)
|
1999-10-22 |
2014-11-26 |
Aventis Pasteur Limited |
Procédé d'induction et/ou amélioration d'une réponse immune vers des antigènes de tumeurs
|
DE19955558C2
(de)
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
US20030198953A1
(en)
|
2000-03-30 |
2003-10-23 |
Spytek Kimberly A. |
Novel proteins and nucleic acids encoding same
|
US20020192763A1
(en)
|
2000-04-17 |
2002-12-19 |
Jiangchun Xu |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
EP1598425A1
(fr)
|
2000-11-23 |
2005-11-23 |
Bavarian Nordic A/S |
Variant modifié du virus de la vaccine ankara
|
US7041870B2
(en)
|
2000-11-30 |
2006-05-09 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
US20150329617A1
(en)
|
2001-03-14 |
2015-11-19 |
Dynal Biotech Asa |
Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
EP2298809A3
(fr)
|
2001-07-12 |
2012-02-15 |
FOOTE, Jefferson |
Anticorps super humanisés
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
ATE290020T1
(de)
|
2001-08-31 |
2005-03-15 |
Avidex Ltd |
Löslicher t zell rezeptor
|
EP1483381A2
(fr)
*
|
2002-03-14 |
2004-12-08 |
Exonhit Therapeutics S.A. |
Variants de kallikrein-2 et kallikreine-3 humaines et leurs utilisations
|
ES2288609T5
(es)
|
2002-04-19 |
2017-11-13 |
Bavarian Nordic A/S |
Virus vaccinia ankara modificado para la vacunación de neonatos
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
US7569664B2
(en)
|
2002-10-09 |
2009-08-04 |
Immunocore Limited |
Single chain recombinant T cell receptors
|
KR101114784B1
(ko)
|
2002-11-12 |
2012-02-27 |
예일 유니버시티 |
아데노바이러스 벡터 백신
|
WO2005048957A2
(fr)
|
2003-02-20 |
2005-06-02 |
Therion Biologics Corporation |
Nouveaux sites d'insertion dans des vecteurs de variole
|
WO2004113571A2
(fr)
|
2003-06-26 |
2004-12-29 |
Exonhit Therapeutics Sa |
Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
|
EP1675607B1
(fr)
|
2003-09-05 |
2015-10-21 |
Oregon Health & Science University |
Molecules mhc monomeres de recombinaison utiles pour la manipulation de lymphocytes t specifiques d'antigenes
|
GB2408507B
(en)
|
2003-10-06 |
2005-12-14 |
Proimmune Ltd |
Chimeric MHC protein and oligomer thereof for specific targeting
|
US20050208020A1
(en)
|
2003-11-12 |
2005-09-22 |
Doolan Denise L |
Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
|
CA2544946A1
(fr)
|
2003-11-24 |
2005-03-06 |
Sidney Kimmel Cancer Center |
Vaccin d'antigene de mucine
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
ATE449105T1
(de)
|
2004-01-23 |
2009-12-15 |
Angeletti P Ist Richerche Bio |
Impfstoffträger für schimpansen-adenovirus
|
CA2588705A1
(fr)
|
2004-11-24 |
2006-06-01 |
St. George's Enterprises Limited |
Diagnostic du cancer de la prostate
|
EP1683808A1
(fr)
|
2005-01-25 |
2006-07-26 |
Het Nederlands Kanker Instituut |
Moyens et méthodes pour résoudre des interactiones non covalentes entre les molécules
|
EP3623473A1
(fr)
|
2005-03-31 |
2020-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
|
DE102005028778A1
(de)
|
2005-06-22 |
2006-12-28 |
SUNJÜT Deutschland GmbH |
Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
|
CA2622295C
(fr)
|
2005-09-12 |
2019-01-15 |
The Regents Of The University Of Michigan |
Fusion geniques recurrentes dans le cancer de la prostate
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
US20100143302A1
(en)
|
2006-03-16 |
2010-06-10 |
Crucell Holland B.V. |
Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
|
PT1999154E
(pt)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Domínios proteicos heterodiméricos modificados
|
WO2007147901A1
(fr)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production d'anticorps bispécifiques
|
EP1878744A1
(fr)
|
2006-07-13 |
2008-01-16 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Epitope-tag pour des récepteurs de cellules T exprimés en surface, leurs utilisations et méthode de selection de cellules hôtes les exprimant
|
GB2442048B
(en)
|
2006-07-25 |
2009-09-30 |
Proimmune Ltd |
Biotinylated MHC complexes and their uses
|
GB2440529B
(en)
|
2006-08-03 |
2009-05-13 |
Proimmune Ltd |
MHC Oligomer, Components Therof, And Methods Of Making The Same
|
US7910565B2
(en)
|
2006-09-01 |
2011-03-22 |
Wisconsin Alumni Research Foundation |
Prostate cancer vaccine
|
ES2500465T3
(es)
|
2006-10-06 |
2014-09-30 |
Bavarian Nordic Inc. |
Virus vaccinia Ankara modificado recombinante que codifica antígeno HER-2 en combinación con un taxano para uso en el tratamiento del cáncer
|
WO2008106615A1
(fr)
|
2007-02-28 |
2008-09-04 |
Numenta, Inc. |
Algorithmes d'apprentissage spatiotemporel dans des réseaux temporels hiérarchiques
|
EP3539567A1
(fr)
|
2007-07-02 |
2019-09-18 |
Etubics Corporation |
Procédés et compositions permettant de produire un vecteur d'adénovirus destiné à être utilisé avec des vaccinations multiples
|
KR20160065985A
(ko)
|
2007-10-18 |
2016-06-09 |
버베리안 노딕 에이/에스 |
전립선 암 치료를 위한 mva의 용도
|
US8748356B2
(en)
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
JP5710261B2
(ja)
|
2007-11-19 |
2015-04-30 |
トランジェーヌ、ソシエテ、アノニムTransgene S.A. |
ポックスウイルス腫瘍細胞崩壊性ベクター
|
JP2011507519A
(ja)
|
2007-12-19 |
2011-03-10 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
|
DK2235064T3
(en)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
US10131921B2
(en)
|
2008-03-06 |
2018-11-20 |
Mayo Foundation For Medical Education And Research |
Single cycle replicating adenovirus vectors
|
CN102119217B
(zh)
|
2008-04-15 |
2015-06-03 |
普洛体维生物治疗公司 |
用于核酸递送的新型制剂
|
EP3062106B1
(fr)
|
2008-04-16 |
2020-11-11 |
The Johns Hopkins University |
Méthode pour déterminer androgènes recepteur variantes dans le cancer de la prostate
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
JP5421374B2
(ja)
|
2008-09-03 |
2014-02-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
悪性神経膠腫におけるイソクエン酸デヒドロゲナーゼ遺伝子および他の遺伝子の遺伝子変化
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
EP2347038A4
(fr)
|
2008-10-14 |
2013-06-12 |
Janssen Biotech Inc |
Procédés d humanisation et de maturation d affinité d anticorps
|
AU2009308935B2
(en)
|
2008-10-31 |
2015-02-26 |
Janssen Biotech, Inc. |
Fibronectin type III domain based scaffold compositions, methods and uses
|
WO2010051367A1
(fr)
|
2008-10-31 |
2010-05-06 |
The Trustees Of The University Of Pennsylvania |
Adénovirus simiens sadv-43, -45, -48, -49 et –50 et leurs utilisations
|
CN102639709A
(zh)
|
2009-01-09 |
2012-08-15 |
密歇根大学董事会 |
癌症中的复现性基因融合体
|
AU2010209938A1
(en)
|
2009-02-02 |
2011-08-25 |
Glaxosmithkline Biologicals Sa |
Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
|
CN102596992B
(zh)
|
2009-02-12 |
2015-09-09 |
詹森生物科技公司 |
基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
|
US8394385B2
(en)
|
2009-03-13 |
2013-03-12 |
Bavarian Nordic A/S |
Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
JP5797190B2
(ja)
|
2009-05-15 |
2015-10-21 |
アイ アール エックス セーラピューティクス, インコーポレイテッド |
ワクチン免疫療法
|
CA2766907A1
(fr)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Molecules d'arn autorepliquantes et leurs utilisations
|
US10464987B2
(en)
|
2009-10-06 |
2019-11-05 |
Abbvie Inc. |
Human single-chain T cell receptors
|
NZ700688A
(en)
|
2009-12-01 |
2016-02-26 |
Shire Human Genetic Therapies |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
GB201002730D0
(en)
|
2010-02-18 |
2010-04-07 |
Uni I Oslo |
Product
|
EP2550529B1
(fr)
|
2010-03-23 |
2021-11-17 |
Iogenetics, LLC. |
Procédés bioinformatiques pour déterminer la liaison de peptides
|
US20170039314A1
(en)
|
2010-03-23 |
2017-02-09 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
MX362513B
(es)
|
2010-03-23 |
2019-01-22 |
Intrexon Corp |
Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos.
|
US9150663B2
(en)
|
2010-04-20 |
2015-10-06 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
EP2569337A1
(fr)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Protéines hétérodimériques et leurs procédés de production et de purification
|
WO2012006369A2
(fr)
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation de grands mammifères à l'aide de faibles doses d'arn
|
RS63817B1
(sr)
|
2010-07-06 |
2023-01-31 |
Glaxosmithkline Biologicals Sa |
Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
DK3243526T3
(da)
|
2010-07-06 |
2020-02-17 |
Glaxosmithkline Biologicals Sa |
Levering af rna til at udløse flere immunsignalveje
|
EP2590626B1
(fr)
|
2010-07-06 |
2015-10-28 |
GlaxoSmithKline Biologicals SA |
Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn
|
EP2420253A1
(fr)
|
2010-08-20 |
2012-02-22 |
Leadartis, S.L. |
Synthèse de molécules polyvalentes et multifonctionnelles avec un domaine de trimérisation de collagène XV
|
EP4119155A1
(fr)
|
2010-08-31 |
2023-01-18 |
GlaxoSmithKline Biologicals S.A. |
Liposomes pegylés pour la délivrance d'arn codant pour un immunogène
|
PL2611467T3
(pl)
|
2010-08-31 |
2022-08-16 |
Glaxosmithkline Biologicals Sa |
Małe liposomy do dostarczania rna kodującego immunogen
|
CN105497883A
(zh)
|
2010-09-29 |
2016-04-20 |
乌第有限合伙公司 |
使用生物相容性的生物可吸收纳米球治疗自身免疫病的方法
|
WO2012044999A2
(fr)
|
2010-10-01 |
2012-04-05 |
Ludwig Institute For Cancer Research Ltd. |
Multimères de protéines réversibles, et leurs procédés de production et d'utilisation
|
RS59589B1
(sr)
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
WO2012089225A1
(fr)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combinaison de vaccination et d'inhibition de la présentation des antigènes restreinte par le cmh de classe i
|
EP2502934B1
(fr)
|
2011-03-24 |
2018-01-17 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Constructions reconnaissant les antigènes à chaîne unique stabilisées par l'introduction de nouvelles liaisons disulfure
|
WO2012149522A1
(fr)
|
2011-04-28 |
2012-11-01 |
Baylor College Of Medicine |
Arn chimériques récurrents enrichis dans le cancer humain de la prostate tenant lieu de biomarqueurs
|
GB201108879D0
(en)
|
2011-05-25 |
2011-07-06 |
Isis Innovation |
Vector
|
EP2723381A4
(fr)
|
2011-06-21 |
2015-03-18 |
Univ Johns Hopkins |
Rayonnement focalisé pour améliorer les thérapies basées sur l'immunité contre les néoplasmes
|
JP2014520806A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
Rna分子の送達のための有用なn:p比を有するリポソーム
|
CA2841047A1
(fr)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Compositions immunogenes et leurs utilisations
|
CA2840989A1
(fr)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Compositions de combinaisons immunogenes et utilisations de celles-ci
|
MX366055B
(es)
|
2011-08-31 |
2019-06-26 |
Novartis Ag |
Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
|
CA2851251C
(fr)
|
2011-10-05 |
2023-09-12 |
Genvec, Inc. |
Adenovirus simiens ou vecteurs adenoviraux simiens et procedes d'utilisation
|
AU2012322704B2
(en)
|
2011-10-11 |
2017-09-07 |
Novartis Ag |
Recombinant self-replicating polycistronic RNA molecules
|
EP2771364B1
(fr)
|
2011-10-27 |
2019-05-22 |
Genmab A/S |
Production de protéines hétérodimères
|
CN104080811B
(zh)
|
2011-11-04 |
2019-09-27 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
DK2794905T3
(da)
|
2011-12-20 |
2020-07-06 |
Medimmune Llc |
Modificerede polypeptider til bispecifikke antistofgrundstrukturer
|
EP2809788B1
(fr)
|
2012-02-02 |
2019-09-04 |
Board Of Regents, The University Of Texas System |
Adénovirus exprimants des antigènes hétérologues associés aux tumeurs
|
US20160078168A1
(en)
|
2012-02-13 |
2016-03-17 |
Splicingcodes.Com |
Fusion transcript detection methods and fusion transcripts identified thereby
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
NZ772318A
(en)
|
2012-04-20 |
2023-06-30 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
DK3401400T3
(da)
*
|
2012-05-25 |
2019-06-03 |
Univ California |
Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering
|
US20150190505A1
(en)
|
2012-07-30 |
2015-07-09 |
Alex Wah Hin Yeung |
Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
|
US10973892B2
(en)
|
2012-09-04 |
2021-04-13 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
WO2014082729A1
(fr)
|
2012-11-28 |
2014-06-05 |
Biontech Ag |
Vaccins individualisés contre le cancer
|
BR112015018989B1
(pt)
|
2013-02-22 |
2023-11-14 |
Curevac Ag |
Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna
|
EP3015477B1
(fr)
|
2013-06-26 |
2021-08-18 |
XLifeSc, Ltd. |
Récepteur de lymphocytes t de haute stabilité et son procédé de préparation et son application
|
US10350275B2
(en)
|
2013-09-21 |
2019-07-16 |
Advantagene, Inc. |
Methods of cytotoxic gene therapy to treat tumors
|
US10035832B2
(en)
|
2013-10-23 |
2018-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
|
CN105828834A
(zh)
|
2013-11-05 |
2016-08-03 |
同源生物服务股份有限公司 |
检查点抑制剂和治疗剂的组合以治疗癌症
|
NZ719232A
(en)
|
2013-11-05 |
2022-04-29 |
Bavarian Nordic As |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
|
WO2015074085A1
(fr)
|
2013-11-18 |
2015-05-21 |
Arcturus Therapeutics, Inc. |
Lipide cationique ionisable pour administration d'arn
|
CN106029889A
(zh)
|
2013-11-22 |
2016-10-12 |
德那翠丝有限公司 |
表达免疫细胞刺激受体激动剂的腺病毒
|
NZ719934A
(en)
|
2013-11-28 |
2022-10-28 |
Bavarian Nordic As |
Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
|
US20170106065A1
(en)
|
2013-12-31 |
2017-04-20 |
Bavarian Nordic A/S |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
|
US9884075B2
(en)
|
2014-01-16 |
2018-02-06 |
California Institute Of Technology |
Domain-swap T cell receptors
|
BR112016018521A2
(pt)
|
2014-02-14 |
2017-10-17 |
Immune Design Corp |
composição, e, kit.
|
CA2941116A1
(fr)
|
2014-02-28 |
2015-09-03 |
Janssen Vaccines & Prevention B.V. |
Vecteurs adenoviaux recombines se repliquant, compositions et procedes pour les utiliser
|
US10441643B2
(en)
|
2014-03-19 |
2019-10-15 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
PT3134131T
(pt)
|
2014-04-23 |
2022-03-24 |
Modernatx Inc |
Vacinas de ácidos nucleicos
|
US20170266270A1
(en)
|
2014-05-13 |
2017-09-21 |
Bavarian Nordic A/S |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
|
ES2851451T3
(es)
|
2014-05-13 |
2021-09-07 |
Bavarian Nordic As |
Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
|
CA2949121A1
(fr)
|
2014-05-15 |
2015-11-19 |
Bristol-Myers Squibb Company |
Traitement du cancer du poumon a l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancereux
|
US20170106067A1
(en)
|
2014-06-12 |
2017-04-20 |
The Johns Hopkins University |
Combinatorial immunotherapy for pancreatic cancer treatment
|
NZ729519A
(en)
|
2014-09-26 |
2024-02-23 |
Bavarian Nordic As |
Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
|
WO2016071343A1
(fr)
|
2014-11-03 |
2016-05-12 |
Immures S.R.L. |
Récepteurs de lymphocytes t
|
CN107949397A
(zh)
|
2015-02-13 |
2018-04-20 |
特兰斯吉恩股份有限公司 |
免疫治疗疫苗和抗体组合治疗
|
WO2016168862A1
(fr)
|
2015-04-17 |
2016-10-20 |
Memorial Sloan-Kettering Cancer Center |
Utilisation de mva ou de mvadeltae3l en tant qu'agents immunothérapeutiques contre des tumeurs solides
|
GB201506642D0
(en)
|
2015-04-20 |
2015-06-03 |
Ucl Business Plc |
T cell receptor
|
US10293058B2
(en)
|
2015-04-22 |
2019-05-21 |
Curevac Ag |
RNA containing composition for treatment of tumor diseases
|
EP3286361A4
(fr)
|
2015-04-23 |
2019-05-08 |
Nantomics, LLC |
Néo-épitopes de cancer
|
BR112017023853A2
(pt)
|
2015-05-06 |
2018-07-17 |
Uti Limited Partnership |
composições de nanopartícula para terapia sustentada.
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
CN116196401A
(zh)
*
|
2015-05-20 |
2023-06-02 |
博德研究所 |
共有的新抗原
|
AU2016270823B2
(en)
|
2015-06-01 |
2020-09-03 |
California Institute Of Technology |
Compositions and methods for screening T cells with antigens for specific populations
|
WO2016197067A1
(fr)
|
2015-06-05 |
2016-12-08 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Vaccin gm-csf/cd40l et polythérapie d'inhibiteur de point de contrôle
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
CN107847544B
(zh)
|
2015-07-20 |
2021-10-15 |
小利兰·斯坦福大学董事会 |
用多聚体结合试剂检测细胞表型和定量
|
GB201513176D0
(en)
*
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
EP3328394A4
(fr)
*
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
Arn épitope peptidiques concatémériques
|
CN107921110B
(zh)
|
2015-08-20 |
2021-10-15 |
扬森疫苗与预防公司 |
治疗性hpv18疫苗
|
US20180318365A1
(en)
|
2015-10-19 |
2018-11-08 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
WO2017070618A1
(fr)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Vaccins anticancéreux
|
CN108473950A
(zh)
|
2015-10-30 |
2018-08-31 |
美国政府卫生与公众服务部 |
靶向癌症治疗
|
KR20180069070A
(ko)
|
2015-11-03 |
2018-06-22 |
얀센 바이오테크 인코포레이티드 |
Tim-3과 특이적으로 결합하는 항체 및 그의 용도
|
EP3383893A4
(fr)
|
2015-12-02 |
2019-06-26 |
Innovative Targeting Solutions Inc. |
Récepteur de lymphocytes t à domaine variable unique
|
MX2018010204A
(es)
|
2016-02-25 |
2019-05-06 |
Memorial Sloan Kettering Cancer Center |
Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
|
CN109152827B
(zh)
|
2016-02-25 |
2023-07-21 |
纪念斯隆凯特琳癌症中心 |
重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
|
CA3015530A1
(fr)
|
2016-03-04 |
2017-09-08 |
New York University |
Vecteurs viraux exprimant de multiples epitopes d'antigenes associes a une tumeur pour induire une immunite antitumorale
|
WO2017162266A1
(fr)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Réplicon d'arn pour une expression génique polyvalente et efficace
|
KR20180129899A
(ko)
|
2016-03-31 |
2018-12-05 |
네온 테라퓨틱스, 인크. |
신생항원 및 이것의 사용 방법
|
CA3056212A1
(fr)
|
2016-04-07 |
2017-10-12 |
Bostongene Corporation |
Elaboration et methodes d'utilisation d'une banque de vaccins therapeutiques contre le cancer contenant des vaccins specifiques de fusions
|
EP3443001A4
(fr)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
Systèmes de biocircuits régulés
|
CA3020426A1
(fr)
|
2016-04-13 |
2017-10-19 |
Synthetic Genomics, Inc. |
Systemes de replicon d'arterivirus recombinant et utilisations correspondantes
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
KR102482867B1
(ko)
|
2016-05-18 |
2023-01-02 |
모더나티엑스, 인크. |
면역 조정 폴리펩타이드를 암호화하는 mRNA의 조합물 및 이의 용도
|
MX2018013509A
(es)
|
2016-05-18 |
2019-03-28 |
Modernatx Inc |
Polinucleotidos que codifican interleucina-12 (il12) y sus usos de los mismos.
|
MA45037A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polythérapie à base d'arnm pour le traitement du cancer
|
MX2018014602A
(es)
|
2016-05-27 |
2019-06-10 |
Etubics Corp |
Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
|
WO2017218689A1
(fr)
|
2016-06-14 |
2017-12-21 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Expression de protéines de ligand d'activation de nkg2d pour sensibiliser les cellules cancéreuses à une attaque par des cellules immunitaires cytotoxiques
|
MX2018015540A
(es)
|
2016-06-20 |
2019-04-11 |
Janssen Vaccines & Prevention Bv |
Promotor bidireccional potente y equilibrado.
|
SG11201811432WA
(en)
|
2016-08-19 |
2019-03-28 |
Curevac Ag |
Rna for cancer therapy
|
TWI796299B
(zh)
*
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
CA3035759A1
(fr)
|
2016-09-02 |
2018-03-08 |
Janssen Vaccines & Prevention B.V. |
Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral
|
SI3293201T1
(sl)
|
2016-09-12 |
2021-03-31 |
Targovax Oy |
Kombinacija zaviralcev adenovirusa in zaviralcev kontrolnih točk za zdravljenje raka
|
KR102605505B1
(ko)
|
2016-09-28 |
2023-11-22 |
버베리안 노딕 에이/에스 |
폭스바이러스에서 이식유전자의 안정성을 강화시키는 조성물 및 방법
|
JP7022123B2
(ja)
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd3に対する二重特異性抗体
|
EP3526332B1
(fr)
|
2016-10-17 |
2024-06-26 |
Janssen Pharmaceuticals, Inc. |
Système réplicon recombinant de virus et leurs utilisations
|
EP3532103A1
(fr)
|
2016-10-26 |
2019-09-04 |
Acuitas Therapeutics, Inc. |
Formulations de nanoparticules lipidiques
|
WO2018093907A1
(fr)
|
2016-11-16 |
2018-05-24 |
PrimeVax Immuno-Oncology, Inc. |
Immunothérapies d'association pour le traitement du cancer
|
EP3544607A4
(fr)
*
|
2016-11-23 |
2020-10-14 |
Gritstone Oncology, Inc. |
Administration virale de néo-antigènes
|
NZ753307A
(en)
|
2016-11-30 |
2023-10-27 |
Advaxis Inc |
Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
|
WO2018102585A1
(fr)
|
2016-11-30 |
2018-06-07 |
Advaxis, Inc. |
Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes
|
EP3548625B1
(fr)
|
2016-12-05 |
2024-06-26 |
Janssen Pharmaceuticals, Inc. |
Compositions et méthodes d'activation d'expression génique
|
WO2018107011A1
(fr)
|
2016-12-08 |
2018-06-14 |
City Of Hope |
Vaccins ciblant p53 et inhibiteurs de la voie pd -1 et leurs procédés d'utilisation
|
US10459372B2
(en)
|
2017-01-31 |
2019-10-29 |
Hewlett-Packard Development Company, L.P. |
Binary ink developer (BID) assembly for liquid electrophotography (LEP) printing device
|
CN110505877A
(zh)
|
2017-02-01 |
2019-11-26 |
摩登纳特斯有限公司 |
Rna癌症疫苗
|
EP3579885A4
(fr)
|
2017-02-07 |
2020-12-16 |
Nantcell, Inc. |
Maximisation de la mémoire de cellules t, compositions et méthodes associées
|
CA3053212C
(fr)
|
2017-02-09 |
2021-04-13 |
Janssen Vaccines & Prevention B.V. |
Promoteur puissant et court pour l'expression de genes heterologues
|
JP7229538B2
(ja)
|
2017-02-10 |
2023-03-01 |
ザ ロックフェラー ユニバーシティー |
薬物標的を特定するための細胞型特異的プロファイリング方法
|
US20200377598A1
(en)
|
2017-03-03 |
2020-12-03 |
New York University |
Induction and Enhancement of Antitumor Immunity Involving Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens and Immune Checkpoint Inhibitors or Proteins
|
WO2018167320A1
(fr)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Vaccin à arn et inhibiteurs de points de contrôle immunitaires pour une thérapie anticancéreuse combinée
|
US20230241207A1
(en)
|
2017-04-03 |
2023-08-03 |
Neon Therapeutics, Inc. |
Protein antigens and uses thereof
|
US20200121774A1
(en)
|
2017-04-19 |
2020-04-23 |
University Of Iowa Research Foundation |
Cancer vaccines and methods of producing and using same
|
JP2020518648A
(ja)
|
2017-05-08 |
2020-06-25 |
グリットストーン オンコロジー インコーポレイテッド |
アルファウイルス新生抗原ベクター
|
CN111107872A
(zh)
|
2017-05-12 |
2020-05-05 |
纪念斯隆-凯特林癌症中心 |
有用于癌症免疫疗法的牛痘病毒突变体
|
JP2020522477A
(ja)
|
2017-06-02 |
2020-07-30 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ |
汎用癌ワクチンおよびそれを製造ならびに使用する方法
|
WO2018234506A2
(fr)
|
2017-06-21 |
2018-12-27 |
Transgene Sa |
Vaccin personnalisé
|
CN111108192B
(zh)
|
2017-07-05 |
2023-12-15 |
Nouscom股份公司 |
非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途
|
FI3652606T3
(fi)
|
2017-07-12 |
2023-03-16 |
Nouscom Ag |
Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon
|
CN111093699A
(zh)
|
2017-07-12 |
2020-05-01 |
Nouscom股份公司 |
用于治疗癌症的新抗原疫苗组合物
|
US11235051B2
(en)
|
2017-07-28 |
2022-02-01 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for heterologous repRNA immunizations
|
GB201713163D0
(en)
*
|
2017-08-16 |
2017-09-27 |
Univ Oxford Innovation Ltd |
HPV vaccine
|
WO2019038388A1
(fr)
|
2017-08-24 |
2019-02-28 |
Bavarian Nordic A/S |
Polythérapie pour le traitement du cancer par administration intraveineuse d'un mva de recombinaison et d'un anticorps
|
US11839655B2
(en)
|
2017-09-01 |
2023-12-12 |
Microvax, Llc |
Combination cancer therapy
|
JP7389741B2
(ja)
|
2017-09-13 |
2023-11-30 |
バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハー |
T細胞受容体または人工t細胞受容体を発現するためのrnaレプリコン
|
BR112020008308A2
(pt)
|
2017-11-03 |
2020-11-17 |
Nouscom Ag |
polipeptídeo, polinucleotídeo, vetor, coleção de dois ou mais vetores, composição farmacêutica e kit
|
WO2019094396A1
(fr)
|
2017-11-07 |
2019-05-16 |
Nektar Therapeutics |
Polyimmunothérapies pour le traitement du cancer
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
MX2020007010A
(es)
|
2018-01-05 |
2020-12-10 |
Ottawa Hospital Res Inst |
Vectores modificados de orthopoxvirus.
|
AU2019205627B2
(en)
|
2018-01-06 |
2024-05-09 |
Emergex Vaccines Holding Limited |
MHC class I associated peptides for prevention and treatment of multiple flavi virus
|
EP3737386A1
(fr)
|
2018-01-11 |
2020-11-18 |
BioNTech RNA Pharmaceuticals GmbH |
Formulation d'administration d'arn
|
EP3740245A4
(fr)
|
2018-01-19 |
2022-01-05 |
Janssen Pharmaceuticals, Inc. |
Induction et amélioration des réponses immunitaires à l'aide de systèmes de réplicon de recombinaison
|
CN111918660A
(zh)
|
2018-01-24 |
2020-11-10 |
复诺健生物科技加拿大有限公司 |
重组病毒疫苗
|
KR20200116086A
(ko)
|
2018-01-26 |
2020-10-08 |
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
종양 치료를 개선하기 위한 종양 미세환경에서 대사 조절인자의 발현
|
US20190367568A1
(en)
|
2018-02-05 |
2019-12-05 |
Nantbio, Inc. |
Calreticulin and fusion proteins
|
US11376290B2
(en)
|
2018-03-14 |
2022-07-05 |
Wuhan Boweid Biotechnology Co., Ltd. |
Recombinant oncolytic virus, synthetic DNA sequence, and application thereof
|
EP3773649A4
(fr)
|
2018-03-28 |
2022-02-23 |
EpicentRx, Inc. |
Vaccins anticancéreux personnalisés
|
US20230149310A1
(en)
|
2018-03-30 |
2023-05-18 |
Arcturus Therapeutics, Inc. |
Lipid particles for nucleic acid delivery
|
TWI816603B
(zh)
|
2018-04-23 |
2023-09-21 |
美商南特細胞公司 |
新抗原表位疫苗及免疫刺激組合物及方法
|
GB201807932D0
(en)
|
2018-05-16 |
2018-06-27 |
Redchenko Irina |
Compositions and methods for inducing an immune response
|
EP3796927A4
(fr)
|
2018-05-23 |
2022-04-20 |
Gritstone bio, Inc. |
Antigènes partagés
|
EP3796930A4
(fr)
|
2018-05-23 |
2022-05-04 |
Gritstone bio, Inc. |
Vecteurs de co-expression d'inhibiteurs de points de contrôle immunitaires
|
AU2019277361A1
(en)
|
2018-05-30 |
2020-12-17 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
WO2019238023A1
(fr)
*
|
2018-06-11 |
2019-12-19 |
Chineo Medical Technology Co., Ltd. |
Vaccins néoantigènes et leurs utilisations
|
EP3587581A1
(fr)
|
2018-06-26 |
2020-01-01 |
GlaxoSmithKline Biologicals S.A. |
Formulations pour vecteurs adénoviraux simiens possédant une stabilité d'entreposage améliorée
|
WO2020014539A1
(fr)
|
2018-07-11 |
2020-01-16 |
Epicentrx, Inc. |
Procédés et compositions pour cibler des cellules cancéreuses pour un traitement
|
WO2020022897A1
(fr)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Procédé de préparation de compositions immunogènes spécifiques à un sujet en s'appuyant sur une base de données de néo-peptides à cadre ouvert de lecture
|
GB201812647D0
(en)
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
CN112996917A
(zh)
|
2018-09-15 |
2021-06-18 |
纪念斯隆凯特琳癌症中心 |
用于癌症免疫疗法的重组痘病毒
|
WO2020072371A1
(fr)
|
2018-10-01 |
2020-04-09 |
The Wistar Institute |
Compositions de vaccins canins contre le mélanome et leurs méthodes d'utilisation
|
JP2022512595A
(ja)
|
2018-10-05 |
2022-02-07 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
組み換えmva、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
|
WO2020073045A1
(fr)
|
2018-10-05 |
2020-04-09 |
Nantcell, Inc. |
Combo cd40 et cd40l dans un véhicule de vaccin à adénovirus
|
KR20210081325A
(ko)
|
2018-10-19 |
2021-07-01 |
노우스콤 아게 |
경골어류 불변 사슬 암 백신
|
MA54192A
(fr)
|
2018-11-07 |
2021-09-15 |
Modernatx Inc |
Vaccins à arn contre le cancer
|
CA3119752A1
(fr)
|
2018-11-07 |
2020-05-14 |
Gritstone Oncology, Inc. |
Vecteurs de neoantigenes d'alphavirus et inhibiteurs d'interferons
|
CN113424264B
(zh)
|
2018-11-15 |
2024-04-12 |
Nouscom股份公司 |
用于生成个性化癌症疫苗的癌症突变选择
|
EP3883599A1
(fr)
|
2018-11-20 |
2021-09-29 |
Bavarian Nordic A/S |
Thérapie pour le traitement du cancer par une administration intratumorale et/ou intraveineuse d'un mva recombinant codant pour 4-1bbl (cd137l) et/ou cd40l
|
EP3893925A4
(fr)
|
2018-12-13 |
2023-01-18 |
Rhode Island Hospital |
Inhibition de l'asph exprimant la croissance et la progression d'une tumeur
|
CA3121430A1
(fr)
|
2018-12-14 |
2020-06-18 |
Glaxosmithkline Biologicals Sa |
Compositions et methodes heterologues de primo-vaccination et de rappel
|
WO2020131586A2
(fr)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Méthodes d'identification de néo-antigènes
|
CN109806390A
(zh)
|
2019-01-07 |
2019-05-28 |
康希诺生物股份公司 |
一种SamRNA疫苗及其制备方法
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
CN115120716A
(zh)
|
2019-01-14 |
2022-09-30 |
健泰科生物技术公司 |
用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
|
CN113507963A
(zh)
|
2019-01-21 |
2021-10-15 |
赛诺菲 |
用于晚期实体瘤癌症的治疗性rna及抗pd1抗体
|
TW202102543A
(zh)
|
2019-03-29 |
2021-01-16 |
美商安進公司 |
溶瘤病毒在癌症新輔助療法中之用途
|
EP3721899A1
(fr)
|
2019-04-08 |
2020-10-14 |
China Medical University |
Polythérapies comprenant un vaccin basé sur des cellules dendritiques et inhibiteur de point de contrôle immunitaire
|
CA3140019A1
(fr)
|
2019-05-30 |
2020-12-03 |
Gritstone Bio, Inc. |
Adenovirus modifies
|
WO2020247547A1
(fr)
|
2019-06-03 |
2020-12-10 |
Geovax, Inc. |
Compositions de vaccins contre le cancer et leurs méthodes d'utilisation
|